Instrument Inactif

Communiqués Grifols, S.A. Other OTC

Actions

GIKLY

US3984382008

Produits pharmaceutiques

Communiqués

24/09	Grifols says plasma donor safety was not compromised as it works to regain licence	AQ
24/09	Health Canada suspends Grifols Winnipeg plasma site over compliance concerns	AQ
16/09	Grifols S A : signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain	PU
14/08	Scrutinized private clinic pauses plasma collection across Canada	AQ
10/08	Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency	AQ
30/07	Changes in the composition of the Board of Directors and Board Committees	AQ
28/07	Grifols increases revenue by 2.6% to EUR3.6 billion, and net profit by 28.7% to EUR227 million until June	AQ
28/07	H1'26 Consolidated Interim Financial Statements	AQ
16/07	Grifols S A : doses first patients in two Phase 3 trials to expand indications of its flagship immunoglobulins	PU
01/07	Grifols S A : reorganizes its operating model to accelerate execution of its strategic roadmap	PU
29/06	Grifols S A : doses first participant in Phase 3 study evaluating novel subcutaneous therapy for alpha1-antitrypsin deficiency	PU
26/06	Delisting (ISIN NUMBER: XS2077646391 (Reg. S) / XS2077647365 (144A))	AQ
26/06	Partial Redemption (ISIN NUMBER: XS2805351843 (Reg. S) / XS2805352064 (144A))	AQ
22/06	Changes in the Composition of the Board of Directors and Board Committees	AQ
18/06	Grifols S A : Shareholders approve key resolutions at the 2026 Annual General Shareholders’ Meeting	PU
18/06	Grifols Communications - Resolutions adopted by the Board of Directors	AQ
15/06	Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.	AQ
12/06	Grifols S A : Egypt continues its growth plan through 2029 with an additional investment of €180 million	PU
03/06	Grifols S A : breaks ground on new manufacturing site in Spain	PU
26/05	Grifols S A : doubles the number of positions in its vocational training program over the past year in Spain	PU
15/05	Ordinary General Shareholders' Meeting	AQ
08/05	Grifols S A : Conference call transcript (a065ff21 61b9 2f2c 67fc 1284cdbb08dct1778229612320)	PU
07/05	Grifols S A : ’ Alternative Performance Measures (a9fc8d43 cea3 1a96 9cf3 2378f1b7cf0dt1778167399199)	PU
07/05	Grifols Q1 2026 Financial Results	AQ
04/05	Grifols S A : strengthens its position among the world’s most sustainable biotechnology companies after improving its Dow Jones Best-in-Class score	PU